Trojan-horse silk fibroin nanocarriers loaded with a re-call antigen to redirect immunity against cancer. Issue 1 (25th January 2023)

• Record Type: Journal Article
• Authors: Bari, Elia; Ferrera, Francesca; Altosole, Tiziana; Perteghella, Sara; Mauri, Pierluigi; Rossi, Rossana; Passignani, Giulia; Mastracci, Luca; Galati, Martina; Astone, Giuseppina Iliana; Mastrogiacomo, Maddalena; Castagnola, Patrizio; Fenoglio, Daniela; Di Silvestre, Dario; Torre, Maria Luisa; Filaci, Gilberto
• Is Part Of: Journal for immunotherapy of cancer. Volume 11:Issue 1(2023)
• Publication Date: 2023-01-25
• Subjects: Immunotherapy, Active -- Lymphocytes, Tumor-Infiltrating -- Melanoma -- Vaccination -- Translational Medical Research; Cancer -- Immunotherapy -- Periodicals; Cancer -- Immunological aspects -- Periodicals; Tumors -- Immunological aspects -- Periodicals; Immunotherapy -- Periodicals; 616.99406105
• DOI: 10.1136/jitc-2022-005916
• Languages: English
• ISSNs: 2051-1426

Abstract

Abstract : Background: The current challenge for immunotherapies is to generate effective antitumor immunity. Since tumor immune escape mechanisms do not impact pre-existing and consolidated immune responses, we tested the hypothesis of redirecting a pregenerated immunity to cancer: to recall a non-tumor antigen response against the tumor, silk fibroin nanoparticles (SFNs) have been selected as 'Trojan-horse' carriers, promoting the antigen uptake by the tumor cells. Methods: SFNs have been loaded with either ovalbumin (OVA) or CpG oligonucleotide (CpG) as antigen or adjuvant, respectively. In vitro uptake of SFNs by tumor (B16/F10 melanoma and MB49 bladder cancer) or dendritic cells, as well as the presence of OVA-specific T cells in splenic and tumor-infiltrating lymphocytes, were assessed by cytometric analyses. Proof-of-concept of in vivo efficacy was achieved in an OVA-hyperimmune B16/F10 murine melanoma model: SFNs-OVA or SFNs-CpG were injected, separately or in association, into the subcutaneous peritumoral area. Cancer dimensions/survival time were monitored, while, at the molecular level, system biology approaches based on graph theory and experimental proteomic data were performed. Results: SFNs were efficiently in vitro uptaken by cancer and dendritic cells. In vivo peritumor administration of SFNs-OVA redirected OVA-specific cytotoxic T cells intratumorally. Proteomics and systems biology showed that peritumoral treatment with either SFNs-OVA or SFNs-CpG dramatically modified tumor microenvironment with respect to the control (CTR), mainly involving functional modules and hubs related to angiogenesis, inflammatory mediators, immune function, T complex and serpins expression, redox homeostasis, and energetic metabolism. Both SFNs-OVA and SFNs-CpG significantly delayed melanoma growth/survival time, and their effect was additive. Conclusions: Both SFNs-OVA and SFNs-CpG induce effective anticancer response through complementary mechanisms and show the efficacy of an innovative active immunotherapy approach based on the redirection of pre-existing immunity against cancer cells. This approach could be universally applied for solid cancer treatments if translated into the clinic using re-call antigens of childhood vaccination.